Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 25;48(2):105-12.
doi: 10.2478/raon-2013-0040. eCollection 2014 Jun.

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer

Affiliations
Review

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer

Tanja Marinko et al. Radiol Oncol. .

Abstract

Background: Trastuzumab therapy given in combination with one of several chemotherapy regimens is currently considered the standard of care for the treatment of early-stage, human epidermal growth factor receptor-2 (HER2) -positive breast cancer. The treatment with trastuzumab is due to a significant impact on the survival part of the standard adjuvant treatment of patients with HER2-positive breast cancer. Patients treated with postoperative breast or chest wall irradiation receive trastuzumab concomitant with radiotherapy. In a small proportion of patients trastuzumab causes cardiotoxicity. Preclinical findings indicate a radiosensibilizing effect of trastuzumab in breast cancer cells, but it is not yet clear whether it radiosensibilizes cells of healthy tissues too.

Conclusions: Special attention is required when left breast or left thoracic wall is irradiated in patient receiving trastuzumab, because long-term effects of the concurrent treatment with trastuzumab and radiotherapy are not yet known. In an era where more patients are surviving a diagnosis of breast cancer, better understanding and earlier detection of therapy-induced cardiac toxicity will be of paramount importance.

Keywords: cardiotoxicity; early breast cancer; radiotherapy; trastuzumab.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Treatment plan for postoperative irradiation of the left breast in patient with early breast cancer - Three dimensional conformal radiation therapy (3DCRT).
FIGURE 2.
FIGURE 2.
Pulsed wave Doppler measurement of flow velocities through the mitral valve annulus showing normal left ventricular filling pattern. (E = early diastolic flow velocity, A = atrial contraction flow velocity).
FIGURE 3.
FIGURE 3.
M mode measurement of left ventricular ejection fraction (LVEF) using the Teichholz method from the parasternal short axis view showing extremely enlarged left ventricle with severely reduced LVEF.
FIGURE 4.
FIGURE 4.
Measurement of tissue Doppler velocities on the mitral annulus from the apical four chamber view showing depressed left ventricular systolic function. (x = systolic velocity, × E = early diastolic velocity, × A = atrial contraction velocity).

Similar articles

Cited by

References

    1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82. - PubMed
    1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84. - PubMed
    1. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36. - PubMed
    1. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneli V, et al. Trastuzumab containing regiments for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243. - PMC - PubMed
    1. Matos E. [Treatment of HER2 positive breast cancer patients]. [Slovenian] Zdrav Vestn. 2012;81:236–45.

LinkOut - more resources